Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Inflamm Bowel Dis. 2012 Mar 29;18(12):10.1002/ibd.22956. doi: 10.1002/ibd.22956

Figure 2.

Figure 2

Methylation levels at the TEPP associated CpG site in the select pediatric PBMC cohort of the study (see Table 2). A. Bisulfite pyrosequencing results from the PBMC samples of the Infinium HumanMethylation450 Microarrays. The significant increase in methylation was confirmed by bisulfite pyrosequencing in the CD and UC cohorts compared to controls (n=6–14). B. Extension of the measurements to larger groups of PBMC DNA from controls and treatment naïve CD patients further supported the validity of our findings (n=19–22). C. The increased level of methylation in treatment naïve (CD) patients was lost when compared to CD patients receiving therapy (CD-rx; 3 biologic monotherapy; 2 biologic+immunomodulator, 2 mesalamine alone, 1 steroid alone, 1 immunomodulator alone, 1 steroid+immunomodulator) (n=10–22).